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Abstract 
Chemotherapy, radiation, and surgery are often ineffective in treating refractory or chronic tumors in 
children. Recent advances in cancer immunotherapy have also improved the outcome of many human 
tumors, resulting in significant responses in patients who have previously refused to respond to other 
treatments. The immune system is made up of cells and proteins that work together to maintain 
immunity against pathogens. Cancer cells can adapt and metastasize over time, express different 
neoantigens, or express more immune-suppressing mechanisms, allowing them to be identified and 
eradicated. In this study, we focus on immunotherapy for pediatric cancer and its progression using 
natural killer (NK) cells, chimeric antigen receptor T cells (CAR-T), and oncolytic virus cells in these 
patients. For all intents and purposes, toxicity is a concern. Although immunotherapy is believed to 
have fewer long-term side effects than chemotherapy and radiation therapy, they may have a high rate 
of short-term side effects, depending on the cause and purpose. These complications can lead to life-
threatening illnesses, from mild illnesses such as fever and headaches to more severe illnesses such as 
autoimmune, neurotoxicity, and opportunistic infections. Any of the problems listed, for example, 
cytokine release syndrome, can be fatal. Different intensities require multiple tests and trials. 
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1. Introduction 
Chemotherapy, radiation, and surgery are often 
ineffective in treating resistant or chronic tumors in 
children. For many cancer patients, immunotherapies 
have been a promising treatment choice [1]. Despite 
advances in chemotherapy and radiotherapy that have 
increased average survival rates for children with 
cancer in recent decades, childhood cancer remains 
the leading risk factor for mortality under the age of 20 
[2]. 
Recent advances in cancer immunotherapy have 
improved the outcome of several human cancers and 
in some cases led to promising responses in patients 
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who were previously unable to respond to other types 
of care [3-6]. Immunotherapy has been used to treat 
cancer since the late 1800s. Wilhelm Bush observed 
tumor regression in 1866 after a rose infection in a 
patient with sarcoma. Shortly afterward, in 1891, 
streptococcus and its toxins were injected into the 
bloodstream by gypsies, and some patients with non-
surgical sarcoma recovered [7-10]. 
The immune system is a diverse and intertwined 
collection of cells and proteins that function together 
to kill pathogens while preserving resistance to 
autoimmunity [11]. Other functions of the immune 
system include focusing on immune monitoring and 
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penetration of immune cells and tumor cytolysis in 
cancer patients. Burnet and Thomas first described 
immunosurveillance in 1957, which occurs when a 
tumor is recognized as 'foreign' in the body [12, 13]. 
The evolution, metastasis, and expression of 
neoantigens, as well as the use of different pathways to 
inhibit the immune system, are all influential 
characteristics of cancer cells. As a result, they are 
resistant to identification and deletion. Thus, the safety 
version should focus on 3 steps, which include 
deletion, balance, and escape [14]. During the removal 
of cancer cells, immune and innate cells detect new 
antigens, followed by the formation of tumor-reacting 
T cells and the removal of the tumor. Any cancer cells 
that exist in the removal process make it to the 
equilibrium level. During the equilibrium time, the 
adaptive immune system keeps the tumor inactive. 
Finally, cancer cells evolve to avoid recognition by the 
immune system, resulting in an escape pathway 
marked by tumor growth and/or T-cell exhaustion [14, 
15]. 
In this study, we intend to examine 
immunotherapy methods to reduce the adverse effects 
of previous traditional therapies, considering the 
differences between pediatric and adult cancers. 
 
2. The difference between cancer in 
children and adults 
In pediatric cancer, most embryonic cells are 
involved in the development of the disease, and thus 
the accumulation of genetic mutations and 
transcriptional abnormalities is thought to cause 
cancer in children [16]. Other research on the causes of 
childhood cancer has shown that children with 
Fanconi anemia are more likely to grow cancer at a 
median age of 16 years [17]. BRCA2 mutations have 
been identified in Fanconi anemia, along with 15 other 
potential mutations, resulting in congenital 
abnormalities, bone marrow dysfunction, and an 
elevated risk of developing myeloid and solid 
malignancies [18, 19]. 
 
3. Chimeric antigen receptors T cells in 
pediatric cancer 
Immunotherapy with chimeric antigen receptors 
T cells (CAR-T), first recorded in the mid-1980s, 
increased hope for cancer care and ignited global 
interest in immuno-oncology [20]. The formation of 
CAR-T cells and natural killer (NK) cells resulted from 
combining the anti-cancer action of immune system 
cells such as T and NK cells with the idea of antibody 
specificity to redirect these cells' cytotoxic activity to 
target tumor cells expressing a specific antigen [21]. 
Tumors' ability to escape the immune system is 
due to the tumor's composition, which modulates the 
function of human leukocyte antigen (HLA) molecules 
or tumor antigens, as previously mentioned. CAR is an 
acceptable therapy choice since it is designed to 
contain a specific antigen without the need for HLA 
neoantigens of tumor genes to overcome the 
difficulties. A chimeric antigen receptor is composed of 
an extracellular domain with an antigen-binding 
domain derived from a monoclonal antibody specific 
for a tumor surface antigen, a spacer domain, a 
transmembrane domain, and an intracellular signal-
transducing chain of the T-cell receptor [22, 23]. A 
specific vector could be used to diagnose most patients 
with cancers that express the target antigen [24]. 
 
4. Natural killer cells  
Human NK cells are formed from multipotent 
CD34+ hematopoietic progenitors in the bone 
marrow. NK cell maturation occurs in both the bone 
marrow and the lymphoid glands and, unlike T cells, 
does not include the thymus [25-27]. NK cells are 
intrinsic lymphocytes that can suppress cancer. Unlike 
T cells, NK cells are activated without any previous 
contact with cancer cells. The function of NK cells is 
determined by a combination of inhibitory activation 
signals by receptor-ligand interaction. Activating 
receptors such as NKp46, NKp44, NKp30, DNAM1, 
and NKG2D identify tumor antigens and activate NK 
cells. These NK cells secrete cytotoxic granules 
containing perforin and granzymes, which directly kill 
cancer cells by inducing apoptosis through various 
mechanisms including the Fas and TRAIL pathways. 
NK cell stimulation in the tumor microenvironment 
can also play a role in dendritic cell and T cell 
recruitment to the tumor site. NK cells may also be 
activated by monoclonal antibodies that target CD16, 
such as daratumumab for multiple myeloma and T-
ALL or rituximab for B cell non-Hodgkin lymphoma 
[28, 29]. Peripheral tissue, cord blood, and induced 
pluripotent stem cells (iPSC) from haploidentical, 
allogeneic, or autologous donors can all be used to 
separate NK cells [30]. NK cells play an important role 
in the transplantation of allogeneic and autologous 
hematopoietic stem cells. A few genes, including KIR, 
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NKG2D, and their ligands, regulate cytotoxicity in 
leukemia. These cells can invade several leukemic cell 
types, including acute myeloid leukemia (AML), 
chronic myeloid leukemia (CML), and chronic 
lymphocytic leukemia (CLL), with little risk of acute 
graft against host disease [31-33]. 
 
5. Pediatric brain tumor immunotherapy 
The immune system finds the central nervous 
system (CNS) to be a privileged location, in addition to 
complementing immune cells and signals that act on 
the rest of the body. The blood-brain barrier (BBB), a 
highly specialized bond between blood and the CNS 
parenchyma caused by capillary endothelium, nursing 
cells, and astrocytes, determines this safe score  [34]. 
Pediatric brain tumors are made up of a variety of 
histologic subtypes that occur with varying degrees of 
aggressiveness in the central nervous system [35]. 
CNS tumors are the most prevalent solid tumors in 
children, as well as the high incidence of cancer-related 
mortality [35]. Although overall childhood cancer 
survival rates have risen significantly in recent 
decades, improvement in pediatric CNS tumors has 
lagged behind that of hematological cancers [36]. 
William Coley introduced bacteria into various tumors 
in the late 1800s to stimulate an immune response, 
and hence the idea of stimulating the immune system 
to combat cancer (also known as rapid 
immunotherapy) was born [8]. Researchers have 
since discovered how the immune system 
communicates with tumor cells in the hopes of 
channeling these abilities to develop effective 
immunotherapies. Antigen presentation on major 
histocompatibility complex (MHC) molecules, as well 
as antigen presentation that is not MHC-dependent, 
are used to activate the immune system. By digesting 
intracellular and extracellular proteins into small 
peptides, extracellular display on class I or class II 
MHC molecules for MHC-dependent activation is 
accomplished [37].T cells use their T-cell receptor 
(TCR) to recognize peptides on the MHC molecule as 
antigens, eliciting an immune reaction  [38]. Peptide 
binding to the MHC is strongly influenced by a 
patient's HLA genotype, which must be taken into 
account when developing and implementing antigen-
based therapies. Antigen epitopes can also stimulate 
the immune system in non-MHC-dependent ways, 
such as antibody-dependent B-cell activation [39]. 
 
6. The role of oncolytic viruses in cancer 
immunotherapy 
Another way to stimulate the immune system to 
fight tumors is to use oncolytic viruses, so viruses that 
are widely used in this field can be called herpes 
simplex virus, adenoviruses, measles virus, and 
poliovirus to attack and infect cells noted cancer. This 
specificity can be achieved by inserting tissue-specific 
promoters that ensure viral replication occurs only in 
target organs, or by removing specific genes that 
ensure viral replication occurs only in actively 
individual cells [40]. An oncolytic virus infection not 
only kills tumor cells directly but also stimulates 
PAMPs and DAMPs, resulting in immunogenic cell 
death and adaptive immune responses [41]. 
 
6. Conclusion 
Given all of the benefits, toxicity is a cause for 
concern. Although immunotherapies are believed to 
have fewer long-term side effects than chemotherapy 
and radiation, they may have a high rate of short-term 
adverse effects that range in magnitude based on the 
agent and the target. This can vary from mild 
inconveniences such as fevers, headaches, and chills to 
more severe conditions such as myalgia, 
autoimmunity, neurotoxicity, and opportunistic 
infections; any of these incidents for example, cytokine 
release syndrome can be fatal. The 
immunosuppressive tumor microenvironment is also 
a recurring issue in solid cancers, since it may reduce 
or eliminate all immunotherapeutic gain [2]. As a 
result, various intensities necessitate several 
measurements and trials. 
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